POST Online Media Lite Edition


NEWLY REPORTED COVID-19 CASES (11.19.2021, 4:50pm CEST, WHO):   India 11,106    Brazil 11,977    United Kingdom 46,858    Russia 37,156    Turkey 22,234    France 19,840    Argentina 1,553    Germany 52,970    Spain 3,932    Columbia 2,257    Italy 10,645    Mexico 3,836    Ukraine 20,050    Poland 23,242    Philippines 1,297    Malaysia 6,380    Netherlands 23,680    Peru 1,370    Thailand 6,855    Czechia 13,374    Canada 2,448    Romania 3,076    Chile 2,611    Serbia 3,219    Sweden 1,210    Portugal 2,398    Vietnam 10,223    Kazakhstan 1,272    Austria 14,212    Hungary 11,289    Greece 7,276    Georgia 4,278    Bulgaria 2,785    Belarus 1,844    Slovakia 7,418    Azerbaijan 2,124    Croatia 7,270    Bolivia 1,119    Ireland 4,646    Lithuania 1,847    Denmark 4,013    South Korea 3,034    Slovenia 3,662    Latvia 1,221    Laos 1,401    China 31    New Zealand 200    Australia 1,302   

Sweden set to grant special permission for new drug to treat COVID-19

Christian Fernsby |
COVID-19 patients in Sweden may now be treated with a drug currently under review by the European Medicines Agency, the country's authority in charge of pharmaceuticals announced on Thursday.

Article continues below

The Swedish Medical Products Agency said it decided to authorize the emergency use of the drug in COVID-19 patients with underlying conditions that make them more vulnerable to the virus.

Bamlanivimab is a monoclonal antibody specifically developed by the U.S.-based pharmaceutical company Eli Lilly. It is targeted against the spike protein of the novel coronavirus and works by inhibiting the virus from infecting cells.

In November, it was authorized for emergency use in the United States and it is also currently under review by the European Medicines Agency.

"It is in the approval process and as the results look promising, we believe that we can take advantage of this drug in a controlled way," Charlotta Bergquist, Group manager Efficacy and Safety at the Swedish Medical Products Agency, told news agency TT.

"Treatment should be started early in the course of the disease for those who risk becoming seriously ill."

The Swedish special permission applies to adults and children over the age of 12 who are at risk of serious illness due to underlying conditions such as immune suppression or medical treatment.

According to the guidelines, treatment should start as soon as possible, but no later than ten days after the first symptoms. However, patients who have already become seriously ill should not be given the drug, as no positive effect has been demonstrated in such conditions.

What to read next

There’s no medicine without side effect
Drug protocol allows doctors to prescribe anticancer medicines outside of approved use
FDA approves 1st new drug for ALS in decades